Zacks Small Cap Issues Positive Forecast for EVAX Earnings

Evaxion Biotech A/S (NASDAQ:EVAX) – Research analysts at Zacks Small Cap boosted their Q1 2025 EPS estimates for Evaxion Biotech A/S in a report released on Wednesday, February 5th. Zacks Small Cap analyst B. Sorensen now expects that the company will earn ($0.75) per share for the quarter, up from their prior forecast of ($1.35). The consensus estimate for Evaxion Biotech A/S’s current full-year earnings is ($0.43) per share. Zacks Small Cap also issued estimates for Evaxion Biotech A/S’s Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($1.49) EPS, Q1 2026 earnings at $0.05 EPS, Q2 2026 earnings at $0.20 EPS, Q3 2026 earnings at $0.21 EPS, Q4 2026 earnings at $0.23 EPS and FY2026 earnings at $0.69 EPS.

Other research analysts have also issued research reports about the company. HC Wainwright reissued a “buy” rating and set a $14.00 price objective on shares of Evaxion Biotech A/S in a research note on Monday. Lake Street Capital reduced their target price on Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday.

Evaxion Biotech A/S Price Performance

Evaxion Biotech A/S stock opened at $2.75 on Friday. The company’s 50-day moving average price is $4.59 and its 200-day moving average price is $10.48. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00. Evaxion Biotech A/S has a twelve month low of $2.22 and a twelve month high of $23.70.

Institutional Trading of Evaxion Biotech A/S

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Catalina Capital Group LLC acquired a new position in Evaxion Biotech A/S (NASDAQ:EVAX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned approximately 2.98% of Evaxion Biotech A/S at the end of the most recent reporting period. 11.04% of the stock is owned by institutional investors and hedge funds.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.